Related Experiment Video
Updated: Aug 26, 2026

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
Published on: August 19, 2014
Analysis of p53 gene mutations in acute myeloid leukemia
1Laboratorio di Ematologia Sperimentale e Genetica Molecolare, Università di Milano, Ospedale Maggiore, Italy.
Abstract:
We have previously reported the absence of mutations within exons 5-9 of the p53 gene in a panel of 30 cases of acute promyelocytic leukemia (APL), which represent the M3 FAB type of acute myeloid leukemia (AML). In the present report, we extend our analysis of p53 gene mutations to 70 cases of AML representative of the other FAB types of the disease, including M1 (16 cases), M2 (20 cases), M4 (17 cases), M5 (12 cases), and M6 (5 cases). DNAs were analyzed for p53 gene mutations in exons 5 to 9 by polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP), and direct sequencing of PCR-amplified products. Mutant p53 alleles were detected in 5 of 70 cases; 1 case in exon 5, 2 cases in exon 6, and 2 cases in exon 7. The alterations of the p53 gene were represented by point mutation leading to an amino acid substitution in four cases, and deletion in the remaining case. In four of the five cases, direct sequencing indicated the loss of the normal p53 allele; in the remaining case, two mutations were detected, presumably involving both p53 alleles. Three cases showed mutations at diagnosis; in the remaining two, the mutations were observed in clinical relapse but not at diagnosis. Our results confirm the relatively low incidence of p53 mutations in AML and further support the evidence that p53 plays a role in leukemogenesis through a recessive mechanism (two-hit model) of inactivation of tumor suppressor activity.
Insights
p53 gene mutations are rare in acute myeloid leukemia (AML) across various French-American-British (FAB) types. Analysis revealed mutations in only 5 of 70 AML cases, suggesting a recessive role in leukemogenesis.
Area of Science:
- Molecular Biology
- Oncology
- Hematology
Background:
- Previous studies indicated no p53 gene mutations in acute promyelocytic leukemia (APL, M3 FAB type).
- The role of p53 mutations in other subtypes of acute myeloid leukemia (AML) remained largely uncharacterized.
Purpose of the Study:
- To investigate the frequency and spectrum of p53 gene mutations in a broader range of AML subtypes beyond APL.
- To further elucidate the mechanism of p53 inactivation in AML pathogenesis.
Main Methods:
- Polymerase chain reaction (PCR) amplification of p53 exons 5-9.
- Single-strand conformation polymorphism (SSCP) analysis.
- Direct sequencing of PCR products to identify mutations.
Main Results:
- Mutant p53 alleles were detected in 5 out of 70 AML cases (M1, M2, M4, M5, M6 FAB types).
- Mutations included point mutations (amino acid substitutions) and one deletion, affecting exons 5, 6, and 7.
- Loss of the normal p53 allele was observed in four cases, supporting a recessive inactivation mechanism.
Conclusions:
- p53 gene mutations occur infrequently in AML across diverse FAB subtypes.
- These findings reinforce the concept of p53 acting as a tumor suppressor through a two-hit recessive mechanism in leukemogenesis.

